CA2478930A1 - Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene - Google Patents

Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene Download PDF

Info

Publication number
CA2478930A1
CA2478930A1 CA002478930A CA2478930A CA2478930A1 CA 2478930 A1 CA2478930 A1 CA 2478930A1 CA 002478930 A CA002478930 A CA 002478930A CA 2478930 A CA2478930 A CA 2478930A CA 2478930 A1 CA2478930 A1 CA 2478930A1
Authority
CA
Canada
Prior art keywords
epitope
construct
cell
antigen
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478930A
Other languages
English (en)
Inventor
Ronald M. Burch
Daniel A. Soltis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of CA2478930A1 publication Critical patent/CA2478930A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur des produits et sur des procédés visant à éliciter une réponse immune cible, et notamment sur des produits de recombinaison d'épitope qui comprennent des mécanismes de ciblage de cellules présentant un antigène.
CA002478930A 2002-04-01 2003-04-01 Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene Abandoned CA2478930A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36945402P 2002-04-01 2002-04-01
US60/369,454 2002-04-01
PCT/US2003/010033 WO2003084467A2 (fr) 2002-04-01 2003-04-01 Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene

Publications (1)

Publication Number Publication Date
CA2478930A1 true CA2478930A1 (fr) 2003-10-16

Family

ID=28791953

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478930A Abandoned CA2478930A1 (fr) 2002-04-01 2003-04-01 Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene

Country Status (6)

Country Link
JP (1) JP2005536987A (fr)
AU (1) AU2003224819A1 (fr)
CA (1) CA2478930A1 (fr)
IL (1) IL164281A0 (fr)
MX (1) MXPA04009554A (fr)
WO (1) WO2003084467A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CA2509684A1 (fr) * 2002-07-03 2004-01-15 Sanofi Pasteur Limited Antigenes tumoraux bfa4 et bcy1 servant a prevenir et/ou a traiter le cancer
CA2514058C (fr) 2003-01-24 2014-05-13 Agensys, Inc. Acides nucleiques et proteines correspondantes dites 254p1d6b utiles pour la detection et le traitement du cancer
US7687465B2 (en) * 2003-04-11 2010-03-30 Kraeftens Bekaempelse Therapeutic cancer vaccine
GB0318247D0 (en) * 2003-08-05 2003-09-10 Royal Veterinary College Antigen delivery system
CA2603180C (fr) 2005-03-23 2015-10-13 Glaxosmithkline Biologicals S.A. Compositions vaccinales contre l'influenza et methode permettant d'immuniser contre la grippe
US8165823B2 (en) * 2005-07-15 2012-04-24 Novartis Ag Pamps, pathogen associated molecular patterns
CA2630023A1 (fr) * 2005-11-14 2007-05-18 Universite Laval Antigene cancereux mage-a9 et ses utilisations
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
CA2651796A1 (fr) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification et utilisation de novopeptides pour le traitement du cancer
PL2043682T3 (pl) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Szczepionka przeciw grypie
AU2007283731B2 (en) * 2006-08-11 2013-10-24 Katholieke Universiteit Leuven Immunogenic peptides and their use in immune disorders
AU2008230240B2 (en) * 2007-03-26 2012-09-13 Academisch Ziekenhuis Leiden H.O.D.N. Lumc PRAME derived peptides and immunogenic compositions comprising these
NZ582823A (en) * 2007-07-27 2012-04-27 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
JP2012511033A (ja) * 2008-12-08 2012-05-17 テゴファーム コーポレーション 多価化合物の可逆阻害用マスキングリガンド
FR2955773B1 (fr) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
US9669091B2 (en) 2013-03-15 2017-06-06 Inovio Pharmaceuticals, Inc. Vaccines having an antigen and interleukin-23 as an adjuvant
US10238741B2 (en) 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
WO2016057986A1 (fr) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Constructions d'épitopes en tandem pour la présentation d'épitopes cd4 et cd8, et leurs utilisations
AU2016271144B2 (en) * 2015-06-01 2018-10-25 Reber Genetics Co., Ltd. Vaccine compositions against porcine reproductive and respiratory syndrome and porcine circovirus associated diseases
BR112018013881A8 (pt) 2016-01-08 2022-11-08 Vaccibody As Vacina de neoepítopo anticâncer terapêutica
WO2017165542A1 (fr) * 2016-03-22 2017-09-28 University Of Florida Research Foundation, Inc. Méthodes, trousse et compositions pour améliorer la thérapie cellulaire
CA3056212A1 (fr) * 2016-04-07 2017-10-12 Bostongene Corporation Elaboration et methodes d'utilisation d'une banque de vaccins therapeutiques contre le cancer contenant des vaccins specifiques de fusions
CN110996971A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化犬癌症疫苗的方法
CA3068437A1 (fr) * 2017-06-27 2019-01-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chascancer Center Genotype du cmh-i limitant le paysage mutationnel oncogene
WO2019055618A1 (fr) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Procédés de classification des réponses à une immunothérapie anticancéreuse
WO2021067550A1 (fr) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer

Also Published As

Publication number Publication date
WO2003084467A2 (fr) 2003-10-16
MXPA04009554A (es) 2005-01-25
IL164281A0 (en) 2005-12-18
WO2003084467A3 (fr) 2006-07-20
AU2003224819A1 (en) 2003-10-20
JP2005536987A (ja) 2005-12-08

Similar Documents

Publication Publication Date Title
CA2478930A1 (fr) Produits de recombinaison d'epitope comprenant des mecanismes de ciblage de cellules presentant un antigene
US20220072113A1 (en) Antigen specific multi epitope vaccines
US9913884B2 (en) HLA-A2 tumor associated antigen peptides and compositions
US9907842B2 (en) Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
US20080279924A1 (en) HLA class I A2 tumor associated antigen peptides and vaccine compositions
TW200930402A (en) Cancer vaccine composition
US10149896B2 (en) MHC-I restricted epitopes containing non-natural amino acid residues
US20110097312A1 (en) Anti-cancer vaccines
WO2001041741A1 (fr) Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i
JP2000502052A (ja) 腫瘍ワクチン及びその製造方法
JP5281515B2 (ja) 腫瘍抗原タンパク質及びその利用
CA2440610C (fr) Induction de l'immunite tumorale par des variantes de la proteine de fixation a folate
De Leo p53-based immunotherapy of cancer
Park Characterization of glucose-regulated protein 170 as a molecular chaperone and its use in cancer immunotherapy
Peng Analysis of immunogenicity of heat shock protein 70-peptide complexes
EP1562622A2 (fr) Epitopes immunogenes pour facteur de croissance fibroplastique 5 (fgf-5) presente par hla-a3 et hla-a2

Legal Events

Date Code Title Description
FZDE Discontinued